AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28640436
Drug: Single-dose cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose cold compress
Trial: 19815485
Drug: PC-SPES 960
RxNorm normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PC-SPES 960 mg t.i.d.
Trial: 19815485
Drug: DES 3
RxNorm normalized name: Electrodes 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DES 3 mg/day
Trial: 18063208
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg IV
Trial: 24061274
Drug: Trivalent seasonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent seasonal influenza vaccine (TIV)
Trial: 26048455
Drug: Bicalutamide 50mg
RxNorm normalized name: BICALUTAMIDE 50MG TAB
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicalutamide 50mg plus dutasteride 3.5mg once daily for 18 months
Trial: 20025366
Drug: Group motivational
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group motivational enhancement therapy (GMET)
Trial: 3897471
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with Adriamycin for six months
Trial: 3277485
Drug: Lorazepam 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 0.06 mg/kg po 90 min preoperatively
Trial: 3277485
Drug: Morphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.1 mg/kg im plus scopolamine 0.006 mg/kg im 60 min preoperatively
Trial: 17000820
Drug: Benzydamine hydrochloride
RxNorm normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzydamine hydrochloride gargle (15 mL, 0.15%)
Trial: 17000820
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and benzydamine hydrochloride gargles
Trial: 14681960
Drug: Eprosartan mesilat
RxNorm normalized name: Eprosartan mesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan mesilat (600 mg daily)
Trial: 14681960
Drug: Other hypotensive
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other hypotensive medicines (control group)
Trial: 6428170
Drug: Propranolol (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (180 mg/d)
Trial: 31014469
Drug: Moderate alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate alcohol intake (0.6 g/kg)
Trial: 29462230
Drug: Oxymetazoline cream
RxNorm normalized name: oxymetazoline Topical Cream
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxymetazoline cream 0.5%, 1.0%, or 1.5% applied topically once or twice daily for 28 days
Trial: 29462230
Drug: Oxymetazoline cream
RxNorm normalized name: oxymetazoline Topical Cream
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxymetazoline cream 1.5% applied twice daily
Trial: 29462230
Drug: Oxymetazoline cream
RxNorm normalized name: oxymetazoline Topical Cream
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxymetazoline cream (all concentrations)
Trial: 27107460
Drug: Ceftazidime-avibactam (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime-avibactam (2000 mg ceftazidime plus 500 mg avibactam, administered via a 2-h intravenous infusion every 8 h for 5-21 days)
Trial: 27107460
Drug: Best available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Best available therapy (mostly carbapenems, 163 (97%) of 168 patients received a carbapenem, 161 (96%) as monotherapy)
Trial: 12453954
Drug: Tadalafil 10
RxNorm normalized name: tadalafil 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 10 mg
Trial: 9972047
Drug: Antiparasitic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiparasitic treatment (after two weeks)
Trial: 9972047
Drug: Trichinella spiralis
RxNorm normalized name: TRICHINELLA SPIRALIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trichinella spiralis infection (before treatment)
Trial: 25874510
Drug: 2 days
RxNorm normalized name: Chapstick 12 Days of Christmas KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 days of octreotide infusion (50 μg/kg)
Trial: 25874510
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of octreotide infusion (50 μg/kg)
Trial: 21823284
Drug: Electroacupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture plus acupoint injection with Methylcobalamin (group A)
Trial: 21823284
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection with Methylcobalamin (group B)
Trial: 19861283
Drug: Defibrase therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrase therapy
Trial: 17559450
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment (ART) with local anaesthesia
Trial: 17559450
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment (ART) without local anaesthesia
Trial: 15768820
Drug: hylan B
RxNorm normalized name: hylan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hylan B gel (n =47)
Trial: 11454146
Drug: GLP-1 administered
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 administered at the onset of a standard meal (550 kCal)
Trial: 11454146
Drug: GLP-1 administered
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 administered at 30 min after the start of the meal
Trial: 11454146
Drug: GLP-1 administered
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 administered at 60 min after the start of the meal
Trial: 29939279
Drug: Anakinra (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (100 mg subcutaneously twice daily for 4 weeks)
Trial: 19259349
Drug: Postoperative prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative prophylactic antibiotics (1.0 g Cefpiramide twice daily until the third day after surgery)
Trial: 19259349
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no postoperative prophylactic antibiotics)
Trial: 8860099
Drug: Captopril 12.5
RxNorm normalized name: captopril 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 12.5 mg (LD-CAP)
Trial: 8860099
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg (HD-CAP)
Trial: 2179367
Drug: Controlled-release albuterol
RxNorm normalized name: albuterol Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release albuterol
Trial: 6814281
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline
Trial: 94402
Drug: Probucol, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol, 500 mg twice daily for 20 weeks
Trial: 25876706
Drug: Oral OKT3
RxNorm normalized name: Humanized OKT3
DrugBank: Teplizumab (DB06606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral OKT3 5.0 mg/day (Group D)
Trial: 25876706
Drug: Oral OKT3
RxNorm normalized name: Humanized OKT3
DrugBank: Teplizumab (DB06606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral OKT3 0.2 mg/day (Group B)
Trial: 12117397
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestin (conjugated equine estrogens 0.625 mg/d plus medroxyprogesterone acetate 2.5 mg/d)
Trial: 10421920
Drug: NaCl post-operative
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl post-operative injection (3 ml)
Trial: 18397971
Drug: Medication Event
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Medication Event Monitoring System (MEMS)
Trial: 3543146
Drug: Intramuscular chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular chloroquine
Trial: 1346408
Drug: Intramuscular artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular artemether and chloroquine
Trial: 6429092
Drug: Dose range
RxNorm normalized name: Orange
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose range of 30 fractions between 1.6 and 2.1 Gy in 6 weeks
Trial: 30804310
Drug: Placebo lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenge (twice daily for 1 month)
Trial: 25407583
Drug: Telephone-administered cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered cognitive behavioral therapy (T‐CBT)
Trial: 20816836
Drug: 180 μg/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 μg/wk peginterferon alfa‐2a for 48 weeks plus 1200 mg/day ribavirin (group A)
Trial: 20816836
Drug: 1400/1600 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1400/1600 mg/day ribavirin (group B)
Trial: 20816836
Drug: 360 μg/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 μg/wk peginterferon alfa‐2a for 12 weeks then 180 μg/wk peginterferon alfa‐2a for 36 weeks plus 1200 mg/day ribavirin (group C)
Trial: 20816836
Drug: 1400/1600 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1400/1600 mg/day ribavirin (group D)
Trial: 11887035
Drug: Medication and
RxNorm normalized name: CVS Health Medication and Topical Refill Pouch KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication and combination treatment
Trial: 11887035
Drug: All four
RxNorm normalized name: Jackson's The Original All Fours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All four treatments
Trial: 9812111
Drug: Haloperidol 2-3
RxNorm normalized name: haloperidol 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 2-3 mg/day (standard dose) in phase B
Trial: 1571340
Drug: Double therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double therapy (cyclosporine and azathioprine)
Trial: 642793
Drug: OAP Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAP Chemotherapy
Trial: 31158607
Drug: E0703 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E0703 (30 mg oral administration)
Trial: 9222732
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg three times daily
Trial: 3687313
Drug: BAY m
RxNorm normalized name: ZINC OXIDE 94 mg in 1 mL TOPICAL LOTION [Cay Skin MoBay Mineral Sunscreen Drops SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY m 1099 (3 X 50 mg/day) in non-diabetic controls
Trial: 3687313
Drug: BAY m
RxNorm normalized name: ZINC OXIDE 94 mg in 1 mL TOPICAL LOTION [Cay Skin MoBay Mineral Sunscreen Drops SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY m 1099 (2 X 25 mg/day) in type II diabetics
Trial: 3687313
Drug: BAY o
RxNorm normalized name: Bay Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY o 1248 (15 mg single dose) in type II diabetics
Trial: 25003151
Drug: High-dose remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose remifentanil (10 ng · mL(‐1))
Trial: 22370325
Drug: Anastrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg daily) alone
Trial: 15696402
Drug: NUTRIOSE FB
RxNorm normalized name: FB-825
DrugBank: FB-825 (DB17598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUTRIOSE FB 30 g/d
Trial: 15696402
Drug: NUTRIOSE FB
RxNorm normalized name: FB-825
DrugBank: FB-825 (DB17598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUTRIOSE FB 60 g/d
Trial: 15696402
Drug: NUTRIOSE FB
RxNorm normalized name: FB-825
DrugBank: FB-825 (DB17598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUTRIOSE FB 80 g/d
Trial: 15696402
Drug: NUTRIOSE FB
RxNorm normalized name: FB-825
DrugBank: FB-825 (DB17598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUTRIOSE FB 10 g/d to 80 g/d
Trial: 941864
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy in three different loci (unilateral loci used for weight loss, bilateral loci, unilateral loci not used for weight loss)
Trial: 30099350
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period (no treatment)
Trial: 7893587
Drug: Fluticasone propionate,
RxNorm normalized name: fluticasone propionate, micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate, 200 micrograms twice daily for 2 weeks
Trial: 27232535
Drug: Ferrous gluconate
RxNorm normalized name: Ferrous Gluconate
DrugBank: Ferrous gluconate (DB14488)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous gluconate daily (37.5 mg iron)
Trial: 25272653
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg)
Trial: 15580061
Drug: 8-week low-cholesterol/low-saturated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week low-cholesterol/low-saturated fat diet (30% total fat, 5% saturated fat, cholesterol <200 mg/daily)
Trial: 17625917
Drug: Reboxetine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (4 mg)
Trial: 2941770
Drug: Amitriptyline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (75 mg)
Trial: 14609009
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg)
Trial: 9209604
Drug: Amrinone (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amrinone (1.0 mg/kg bolus followed by 10 micrograms/kg/min)
Trial: 27798452
Drug: Modified double-injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified double-injection group (MDI group)
Trial: 27798452
Drug: Traditional double-injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional double-injection group (DI group)
Trial: 21872933
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment (ET) - laser photocoagulation at high-risk prethreshold ROP
Trial: 25968407
Drug: Pravastatin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (both doses)
Trial: 19217695
Drug: 4% lidocaine
RxNorm normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% lidocaine cream
Trial: 17760733
Drug: Metformin 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1500 mg daily for 24 weeks
Trial: 23885611
Drug: Heparin sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin sodium group (group B)
Trial: 10618543
Drug: Hexavalent meningococcal
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexavalent meningococcal outer-membrane-vesicle vaccine (7.5 and 15 microg of individual PorA proteins)
Trial: 10618543
Drug: Hexavalent meningococcal
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexavalent meningococcal outer-membrane-vesicle vaccine
Trial: 10376615
Drug: Angiotensin‐converting‐enzyme (ACE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin‐converting‐enzyme (ACE) inhibitor
Trial: 10376615
Drug: Calcium‐channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium‐channel blocker
Trial: 8910814
Drug: Hyperglycaemia (20-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycaemia (20-30 mmol/l)
Trial: 8910814
Drug: Euglycaemia (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycaemia (5-10 mmol/l)
Trial: 25713599
Drug: Donepezil 5
RxNorm normalized name: donepezil 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 5 mg
Trial: 11079739
Drug: IGT/NFG (2-h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGT/NFG (2-h glucose 7.8-11.0 mmol/l, fasting glucose < 6.1 mmol/l)
Trial: 6375803
Drug: Bisacodyl (1.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisacodyl (1.25, 2.5, and 5 mg)
Trial: 28197834
Drug: Canagliflozin 300
RxNorm normalized name: canagliflozin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 300 mg
Trial: 15759025
Drug: Low-dose combination
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combination therapy (CCBs + ARBs)
Trial: 15759025
Drug: High-dose CCBs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose CCBs
Trial: 10223241
Drug: NEO chemoendocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEO chemoendocrine therapy
Trial: 10223241
Drug: ADJ chemoendocrine
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADJ chemoendocrine therapy
Trial: 25621943
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IAI) 0.5 mg every 4 weeks
Trial: 25621943
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks
Trial: 25621943
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IAI) as-needed after 3 monthly doses
Trial: 24101054
Drug: Bevacizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (15 mg/kg, day 1, 21-day cycle) plus erlotinib (150 mg per day)
Trial: 22099189
Drug: EPO treatment
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO treatment (200 IU/kg•d, 3 times weekly for 2 to 4 weeks)
Trial: 19085014
Drug: EPO treatment
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO treatment
Trial: 15313090
Drug: Special training
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special training program using Solutions for Smoking as the main teaching tool
Trial: 11776303
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (s.c. enoxaparin) and low dose aspirin
Trial: 9763070
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg
Trial: 29322401
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day mirabegron
Trial: 24239431
Drug: Bupropion-SR 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion-SR 150 mg
Trial: 22370318
Drug: Vandetanib 300
RxNorm normalized name: vandetanib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 300 mg/d
Trial: 20480132
Drug: Aliskiren 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 600 mg
Trial: 16177470
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (0.8 mg) after mifepristone (200 mg)
Trial: 16177470
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol (0.8 mg) after mifepristone (200 mg)
Trial: 16177470
Drug: Continued oral
RxNorm normalized name: Entex HC Discontinued Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued oral misoprostol (0.4 mg twice daily for 7 days)
Trial: 10094948
Drug: 0.02 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 mg/kg midazolam
Trial: 3908504
Drug: Topical acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical acyclovir
Trial: 29807962
Drug: 0.8% hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8% hyaluronic acid gel (GENGIGEL®)
Trial: 12435254
Drug: Clopidogrel loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel loading dose (300 mg) followed by clopidogrel (75 mg/d) for 12 months
Trial: 12435254
Drug: Clopidogrel loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel loading dose (300 mg) given at least 6 hours before PCI
Trial: 7496640
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for major depressive disorder (specific treatments not detailed), lasting 16 weeks.
Trial: 1685465
Drug: cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine 800 mg at night (n=8)
Trial: 1685465
Drug: ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ranitidine 150 mg twice daily (n=10)
Trial: 1685465
Drug: famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 40 mg at night (n=8)
Trial: 26201996
Drug: Posterior subtenon
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior subtenon injection of 20 mg triamcinolone acetonide